Medpassport is our flagship software platform for patient relationship management. It is accessible online via PC or mobile device.
Medpassport collects and analyzes patient data, and also facilitates communication between healthcare professionals and patients.Read more
Diabeo: innovative tool for diabetes management
Diabeo,an innovative telemedicine solution for diabetes management, is the result of a joint venture between CERITD (a leading French diabetes research institute), Voluntis and Sanofi.
Diabeo supports diabetes treatment. It has already proven its clinical efficacy among type 1 diabetes patients.Read more
10 years' experienceRead more
505 000 patients record managed
50 solutions available in 10 countries
20 therapeutic areas covered
ISO 9001 and ISO 13485 certifications
Patient relationship management
Voluntis is a medical software company. We develop web and mobile solutions for monitoring and supporting patients in order to help healthcare organizations.
Therapeutic software solutions
As a manufacturer of medical software devices, Voluntis provides healthcare professionals and patients with innovative solutions that signal the advent of connected treatment.
Voluntis is invited by the Care Continuum Alliance to speak at the International Symposium on Wellness & Chronic Care. Pierre Leurent, CEO and founder of Voluntis, will share his view regarding the development, the evaluation and the reimbursement of mobile and cloud-based diabetes management solutions.Read more
Voluntis exhibits at congress HIT (HEALTH information TECHNOLOGIES) FROM 22 TO 25 MAY 2012 – Porte de Versailles, Paris, France – Section Syntec HEALTH. Voluntis has the pleasure to welcome you during this event at our stand. Come and visit us during these four days!Read more
- Voluntis announces it closed its third round of funding of Euro 5.1M with CapDecisif Management, Sham, CM-CIC Capital Innovation and Sudinnova, shareholders of the company since 2007. This new round of venture funding takes place in a period of fast growth and business evolution of the company.Read more
Voluntis has signed a joint venture agreement with the French subsidiary of Sanofi and CERITD (a French diabetes research organization) to develop Diabeo, an innovative telemedicine solution planned for launch in France in 2014. Diabeo is made up of three intelligent systems.Read more
- On December 7, 2010, Voluntis announced the opening of its US subsidiary at a press conference at Alcazar in Paris. Voluntis CEO Pierre Leurent presented the CoaguCheck-Link service, which was launched by Roche in the United States and implemented using medpassport.Read more
Pierre Leurent, CEO of Voluntis, attended the event “Prospective in Healthcare 2025” (“Colloquium Prospective Santé 2025”), and participated in the round table "Towards new relations between actors for an efficiency of the health system".Read more
- Like each year, Voluntis is present at the Annual Diabetes Technology Meeting which will be held on November 11-13, 2010 at the Marriott Bethesda North in Bethesda, Maryland, US. This meeting is an excellent opportunity for us to meet leading scientists in the field of diabetes research and learn about the latest technological advances for people with diabetesRead more
Thanks to its new medical and organizational modules, the brand-new version of medpassport 4.2 is particularly well adapted to the needs of Pharmaceutical Industry, Health Networks, public and private Insurers, medico-technical Service Providers and Sports Organizations. The business functions (medical protocol, questionnaires, Vidal module, alerts) were enriched as well as numerous synthestic views were added.Read more
- This year, the 46th EASD Annual Meeting (the principal European Congress in Diabetes) takes place in Stockholm from the 20th to 24th of September. As in previous years, a team from Voluntis is present, led by the CEO Pierre Leurent.Read more